Sector News

Monsanto bid may mean Bayer will cut pharma R&D spending

June 1, 2016
Energy & Chemical Value Chain

The proposed $62bn merger with agrochemical firm Monsanto would jeopardise Bayer’s pharmaceutical business, according to a BMI Research analyst.

> Read the full article on the in-Pharma Technologist website

By Dan Stanton

Source: in-Pharma Technologist

comments closed

Related News

September 7, 2024

US researchers uncover catalytic methods for vaporizing plastic waste

Energy & Chemical Value Chain

Researchers have developed a new chemical process capable of vaporizing plastics and converting them into hydrocarbon building blocks for new materials. This catalytic process breaks down two of the most dominant types of post-consumer plastic waste — PE and PP — into monomers, offering a potential solution to packaging waste management.

September 7, 2024

New Neste CEO to take up role in October

Energy & Chemical Value Chain

On 2 September 2024 it has been agreed that Heikki Malinen will assume the role of Neste’s President and CEO on 15 October 2024. He succeeds Matti Lehmus, who will continue as the President and CEO of Neste until 14 October 2024 and then act as an advisor to the company and its management until mid-November 2024 to ensure a smooth transition.

September 7, 2024

Eni, Socar sign MOU for potential biofuels, biorefineries value chain

Energy & Chemical Value Chain

Eni SpA (Rome) and Azerbaijan’s state energy company Socar (Baku) have signed a memorandum of understanding (MOU) for potential cooperation in the biofuels production chain, including the possible conversion of conventional crude oil refineries into biorefineries. A schedule for potential projects was not given.